公开(公告)号：US20220331422A1

公开(公告)日：2022-10-20

申请号：US17829004

申请日：2022-05-31

Applicant: CureVac AG ,  GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Nicole ROTH ,  Diego Chaves MORENO ,  Hans Wolfgang GROßE ,  Dominik VAHRENHORST ,  Susanne RAUCH

IPC: A61K39/215 ,  A61K9/127 ,  A61K31/713 ,  C12N15/113 ,  A61K9/51

Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

公开(公告)号：US20220305112A1

公开(公告)日：2022-09-29

申请号：US17680433

申请日：2022-02-25

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Robbert Gerrit VAN DER MOST

IPC: A61K39/215 ,  A61K39/39

Abstract: The present invention relates to immunisation with a coronavirus spike antigen and a squalene emulsion adjuvant to elicit broad immune responses, and to related aspects.

公开(公告)号：US20220273789A1

公开(公告)日：2022-09-01

申请号：US17627998

申请日：2020-07-20

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Normand BLAIS ,  Cindy CASTADO ,  Johann MOLS ,  Lionel SACCONNAY ,  Marie TOUSSAINT ,  Newton Muchugu WAHOME ,  Giulietta MARUGGI

IPC: A61K39/245 ,  C07K14/005 ,  A61P31/22 ,  A61P37/04

Abstract: The present invention relates to viral Fc receptor or immunogenic fragments thereof for treating a viral infection in a subject and, in particular, a herpes vims infection. The present invention also relates to a heterodimer comprising or consisting of an Fc receptor from a HSV vims or an immunogenic fragment thereof and a binding partner from said HSV vims or a fragment thereof, for use in therapy.

公开(公告)号：US20220211859A1

公开(公告)日：2022-07-07

申请号：US17608230

申请日：2020-05-07

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Ralph Leon BIEMANS ,  Elisabeth Marie Monique BERTAUD

IPC: A61K47/64 ,  A61K39/09 ,  A61P31/04 ,  B01D15/38 ,  B01D15/42

Abstract: This application relates to methods for the production of polysaccharide antigen-carrier protein conjugates, in particular conjugates of Group B Streptococcus (GBS) capsular polysaccharide and a carrier protein, in particular CRM197. The methods comprise a hydroxyapatite chromatography step in order to separate the conjugate from free polysaccharide and free carrier protein.

公开(公告)号：US20220192997A1

公开(公告)日：2022-06-23

申请号：US17683931

申请日：2022-03-01

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew GEALL ,  Christian Walter MANDL ,  Derek Thomas O'HAGAN ,  Manmohan SINGH

IPC: A61K9/50 ,  A61K39/155 ,  A61K39/245 ,  C12N15/86 ,  C12N15/88 ,  A61K39/12 ,  A61K9/127 ,  A61K9/00

Abstract: Nucleic acid immunisation is achieved by delivering a self-replicating RNA encapsulated within a small particle. The RNA encodes an immunogen of interest, and the particle may deliver this RNA by mimicking the delivery function of a natural RNA virus. Thus the invention provides a non-virion particle for in vivo delivery of RNA to a vertebrate cell, wherein the particle comprises a delivery material encapsulating a self-replicating RNA molecule which encodes an immunogen. These particles are useful as components in pharmaceutical compositions for immunising subjects against various diseases.

公开(公告)号：US11339367B2

公开(公告)日：2022-05-24

申请号：US15094077

申请日：2016-04-08

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Christiane Gerke ,  Francesco Berlanda Scorza ,  Allan Saul ,  Luana Maggiore

IPC: C12N1/20 ,  C07K14/25 ,  A61K39/00 ,  A61K35/12

Abstract: Hyperblebbing Shigella strains are generated by disrupting one or more components of the Tol-Pal system. The blebs from these strains are useful immunogens for vaccination. The individual proteins found in these blebs can also be used as immunogens.

公开(公告)号：US20220144865A1

公开(公告)日：2022-05-12

申请号：US17582150

申请日：2022-01-24

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Helene G. BAZIN-LEE ,  Jay T. EVANS ,  David BURKHART ,  Michael COCHRAN ,  David A. JOHNSON

IPC: C07F9/6561

Abstract: This invention relates inter alia to novel imidazoquinoline derivatives and their use in therapy, particularly as vaccine adjuvants.

公开(公告)号：US20220054632A1

公开(公告)日：2022-02-24

申请号：US17299347

申请日：2019-12-11

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Rainer FOLLADOR ,  Stefan Jochen KEMMLER ,  Michael Thomas KOWARIK ,  Gerald Johann POSCH

IPC: A61K39/385 ,  C07K14/22 ,  C07K14/28 ,  C07K14/33 ,  C07K14/34 ,  C07K14/21 ,  C07K14/205 ,  C07K14/245 ,  C12N15/70

Abstract: Carrier proteins modified to incorporate one or more pilin glycotags and applications thereof for O-linked glycosylation are provided. In particular, a modified carrier protein comprising a carrier protein that comprises at least one GlycoTag, wherein the at least one GlycoTag is a Neisseria gonorrhoeae PglL GlycoTag (NgGlycoTag), Neisseria lactamica PglL GlycoTag (NlGlycoTag), or Neisseria shayeganii GlycoTag (NsGlycoTag), or combinations thereof is provided, together with nucleic acids and vectors encoding the modified carrier protein, host cells comprising these modofoed carrier proteins or nucleic acids encoding them, bioconjugates, methods of making bioconjugates and uses of the bioconjugates.

公开(公告)号：US11248012B2

公开(公告)日：2022-02-15

申请号：US16989235

申请日：2020-08-10

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Helene G. Bazin-Lee ,  Laura S. Bess ,  David A. Johnson

IPC: C07F9/6558 ,  C07F9/10 ,  C07F9/6561

Abstract: The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)-active and toll-like receptor (TLR8)-active imidazoquinolines and oxoadenines.

公开(公告)号：US20220008529A1

公开(公告)日：2022-01-13

申请号：US16636560

申请日：2018-08-08

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Renzo ALFINI ,  Roberta DI BENEDETTO ,  Francesca MICOLI ,  Allan James SAUL

IPC: A61K39/095 ,  A61K35/74 ,  A61K39/108 ,  A61K47/69

Abstract: The present invention is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to multiple antigens to form multi functionalized nOMV-antigen conjugated derivatives, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates are also provided.